The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma

Article Urology & Nephrology

2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma

Jens Bedke et al.

Summary: Adjuvant pembrolizumab, an immune checkpoint inhibitor, showed significant improvement in disease-free survival (DFS) for high-risk clear cell renal cell carcinoma patients. However, the overall survival (OS) data are not yet available.

EUROPEAN UROLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial

R. J. Motzer et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial

Sumanta Kumar Pal et al.

Summary: The objective of this study was to determine if adjuvant atezolizumab delayed recurrence in renal cell carcinoma patients with an increased risk of recurrence. The study found that adjuvant atezolizumab did not improve clinical outcomes in patients with renal cell carcinoma.

LANCET (2022)

Add to Collection

Article Oncology

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles et al.

LANCET ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial

M. Allaf et al.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Editorial Material Urology & Nephrology

New Insights into Adjuvant Therapy in Renal Cell Carcinoma: Is the Chapter of VEGF Inhibitors Definitely Closed?

Florent Peyraud et al.

EUROPEAN UROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

T. K. Choueiri et al.

Summary: The study showed that adjuvant pembrolizumab therapy significantly improved disease-free survival compared to placebo among high-risk kidney cancer patients after surgery, with a positive impact on overall survival as well.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology